“Should Anti-CGRP Monoclonal Antibodies Always Be the Drug of First Choice for Migraine Prophylaxis in Brazil? - a Pharmacoeconomic Study”. Headache Medicine, vol. 15, no. 3, Sept. 2024, pp. 170-4, https://doi.org/10.48208/HeadacheMed.2024.34.